These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 25226154)
1. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody. Siebert N; Seidel D; Eger C; Jüttner M; Lode HN PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154 [TBL] [Abstract][Full Text] [Related]
2. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO. Siebert N; Eger C; Seidel D; Jüttner M; Lode HN J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144 [TBL] [Abstract][Full Text] [Related]
3. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab. Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592 [TBL] [Abstract][Full Text] [Related]
4. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727 [TBL] [Abstract][Full Text] [Related]
5. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481 [TBL] [Abstract][Full Text] [Related]
6. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P Front Immunol; 2021; 12():690467. PubMed ID: 34367149 [TBL] [Abstract][Full Text] [Related]
7. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Chen RL; Reynolds CP; Seeger RC Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607 [TBL] [Abstract][Full Text] [Related]
8. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies. Parsons K; Bernhardt B; Strickland B Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066 [TBL] [Abstract][Full Text] [Related]
10. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD Siebert N; Zumpe M; Jüttner M; Troschke-Meurer S; Lode HN Oncoimmunology; 2017; 6(10):e1343775. PubMed ID: 29123953 [TBL] [Abstract][Full Text] [Related]
11. Reduction of CD11b Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046 [TBL] [Abstract][Full Text] [Related]
12. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486 [TBL] [Abstract][Full Text] [Related]
13. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368 [TBL] [Abstract][Full Text] [Related]
14. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy. Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. Siebert N; Eger C; Seidel D; Jüttner M; Zumpe M; Wegner D; Kietz S; Ehlert K; Veal GJ; Siegmund W; Weiss M; Loibner H; Ladenstein R; Lode HN MAbs; 2016; 8(3):604-16. PubMed ID: 26785755 [TBL] [Abstract][Full Text] [Related]
16. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293 [TBL] [Abstract][Full Text] [Related]
17. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma. Eger C; Siebert N; Seidel D; Zumpe M; Jüttner M; Brandt S; Müller HP; Lode HN PLoS One; 2016; 11(3):e0150479. PubMed ID: 26967324 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. Terme M; Dorvillius M; Cochonneau D; Chaumette T; Xiao W; Diccianni MB; Barbet J; Yu AL; Paris F; Sorkin LS; Birklé S PLoS One; 2014; 9(2):e87210. PubMed ID: 24520328 [TBL] [Abstract][Full Text] [Related]
20. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study. Ladenstein R; Weixler S; Baykan B; Bleeke M; Kunert R; Katinger D; Pribill I; Glander P; Bauer S; Pistoia V; Michon J; Garaventa A; Lode HN MAbs; 2013; 5(5):801-9. PubMed ID: 23924804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]